David Meeker, M.D.
Position: Chief Executive Officer (CEO)
Previous: Chief Operating Officer (COO)
Joined Genzyme: 1994
Education: M. D. from University of Vermont Medical School, Advanced Business Management Program from Harvard Business School
Dr. Meeker joined Genzyme in 1994 as medical director to work on their Cystic Fibrosis Gene therapy program. He has since held the role of VP Medical Affairs, President of Global rare Disease in which he oversaw the launches of Aldurazyme, Fabrazyme and Myozyme.
Prior to joining Genzyme Dr Meeker was a director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic, and an assistant professor of medicine at Ohio State University with more than 40 published articles under his belt.
Dr Meeker is also a board member of the Biotechnology Industry Organization (BIO), Prize4Life, the California Institute of Healthcare, and Savient Pharmaceuticals.